Emestedastat - Actinogen Medical
Alternative Names: UE-2343; XanamemLatest Information Update: 04 Jul 2025
At a glance
- Originator University of Edinburgh
- Developer Actinogen Medical
- Class Antidementias; Azabicyclo compounds; Ketones; Pyrazoles; Pyrimidines; Small molecules; Thiophenes
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Alzheimer's disease
- Phase II Major depressive disorder
- Preclinical Fragile X syndrome
Most Recent Events
- 30 Jun 2025 Actinogen Medical plans a Type-C meeting with the US FDA for Alzheimer's disease in second half of 2025
- 30 Jun 2025 Actinogen medical plans a XanaMIA-DUR clinical trial for Alzheimer's disease in first quarter of 2026
- 30 Apr 2025 Actinogen Medical completed a Type-C meeting with the US FDA for Major depressive disorder prior to April 2025